AgenT-797

Phase 3Biologic

MMiNK Therapeutics

AgenT-797 is one of 71 biologic programs targeting Pneumonia. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

PneumoniaRecruiting

Gastroesophageal Junction CancerRecruiting

Colorectal Cancer MetastaticRecruiting

Stem Cell TransplantationNot yet recruiting

PneumoniaPhase 3

Recruiting

Gastroesophageal Junction CancerPhase 2

Recruiting

Colorectal Cancer MetastaticPhase 2

Recruiting

Stem Cell TransplantationPhase 1

Not yet recruiting

Competition

Competitive Landscape

152 competitors in Pneumonia

#DrugCompanyPhaseTrials

AgenT-797

MMiNK Therapeutics

Phase 3

2 2

Jakafi

Incyte

Preclinical

1 3

Primaquine

Sanofi

Preclinical

1 4

Acanya

Pfizer

Preclinical

1 5

Prevacid

Takeda

Preclinical

1 6

Plaquenil

Jazz Pharmaceuticals

Preclinical

1 7

Avlosulfon

AAlmirall, S.A.

Preclinical

4 8

Retrovir

BBp Consulting, Inc

Preclinical

2 9

Primsol

CConrado Roberto Hoffmann Filho

Preclinical

2 10

Virazole

CConrado Roberto Hoffmann Filho

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2027

Phase 2Recruiting

Gastroesophageal Junction Cancer

NCT06251973

Phase 2Recruiting

Pneumonia

NCT07615010

Q4 2028

Phase 2Recruiting

Colorectal Cancer Metastatic

NCT07550088

Q4 2029

Phase 1Not yet recruiting

Stem Cell Transplantation

NCT07758218

Phase 3Not yet recruiting

Pneumonia

NCT07492875

Clinical

Trials by Indication[1]

Pneumonia2 trials

Study of Nogapendekin Alfa Inbakicept and iNKT Cells in Critically Ill Adults With Severe Community-Acquired Pneumonia

Not yet recruiting·IImmunityBio, Inc.·Phase 3·NCT07492875·10 enrolled

Phase 2 Adaptive Randomized, Placebo -Controlled Trial of agenT-797 + Standard of Care Vs. Placebo + Standard of Care in Severe Pneumonia With Moderate to Severe Acute Hypoxemic Respiratory Failure (AHRF) By Global ARDS Criteria

Recruiting·MMiNK Therapeutics·Phase 2·NCT07615010·90 enrolled

COVID-191 trial

A Clinical Trial to Evaluate the Safety of agenT-797 in COVID-19 Participants With ARDS

Completed·MMiNK Therapeutics·Phase 1·NCT04582201·20 enrolled

Multiple Myeloma1 trial

agenT-797 in Participants With Relapsed/Refractory Multiple Myeloma

Completed·MMiNK Therapeutics·Phase 1·NCT04754100·13 enrolled

Refractory Solid Tumors1 trial

A Study Investigating agenT-797 in Participants With Relapsed/Refractory Solid Tumors

Completed·MMiNK Therapeutics·Phase 1·NCT05108623·34 enrolled

Gastroesophageal Junction Cancer1 trial

A Study of agenT-797 in Combination With Botensilimab, Balstilimab, Ramucirumab, and Paclitaxel for People With Esophageal, Gastric, or Gastro-esophageal Junction Cancer

Recruiting·MMemorial Sloan Kettering Cancer Center·Phase 2·NCT06251973·37 enrolled

2 more indications

Stem Cell Transplantation1 trial

UW26004: Phase I Trial of Allogeneic iNKT Cell Therapy (agenT-797) in Patients Undergoing Allogeneic Hematological Stem Cell Transplantation (SCT)

Not yet recruiting·UUniversity of Wisconsin, Madison·Phase 1·NCT07758218·22 enrolled

Colorectal Cancer Metastatic1 trial

A Single-Arm, Phase II Study Evaluating Combination Balstilimab Plus Botensilimab With AgenT-797 in Previously Treated Patients With pMMR Metastatic CRC With Liver Metastases

Recruiting·DDarren Sigal, MD·Phase 2·NCT07550088·17 enrolled

Sources

References

[1]
ClinicalTrials.gov — 8 trial records for AgenT-797. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — AgenT-797 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for AgenT-797. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — MiNK Therapeutics company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Biologic[2]
Highest Phase: Phase 3[1]
Company: MMiNK Therapeutics

AgenT-797

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q3 2027

Q4 2028

Q4 2029

Trials by Indication[1]

Pneumonia2 trials

COVID-191 trial

Multiple Myeloma1 trial

Refractory Solid Tumors1 trial

Gastroesophageal Junction Cancer1 trial

Stem Cell Transplantation1 trial

Colorectal Cancer Metastatic1 trial

References

Drug Info

Quick Facts

Related News